Efpeglenatide: The Weekly GLP-1 With Cardio-Renal Benefits
Efpeglenatide is an exendin-based weekly GLP-1 that cut heart and kidney events in the AMPLITUDE-O trial and drove up to 7.2 kg of weight loss. Here's the full evidence.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on July 12, 2026
Our medical review process ensures clinical accuracy and patient safety.
Most GLP-1 receptor agonists on the market descend from human GLP-1. Efpeglenatide takes a different route: it is built from exendin-4, the peptide originally isolated from Gila monster venom, fused to a human antibody fragment to extend its half-life to a full week. That structural choice matters, because efpeglenatide is the only exendin-based GLP-1 to complete a dedicated cardiovascular outcomes trial — and it succeeded, cutting major heart and kidney events in people at the highest risk. Add placebo-adjusted weight loss of up to 7.2 kg in early trials, and efpeglenatide becomes a drug worth understanding, even though it has never reached a pharmacy shelf.
Evidence: "Among patients with type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus at least one additional cardiovascular risk factor, efpeglenatide reduced the risk of cardiovascular events." — Gerstein HC, et al. N Engl J Med. 2021. 10.1056/NEJMoa2108269
What Makes Efpeglenatide Structurally Different
The GLP-1 class splits into two chemical families. Semaglutide, liraglutide, and dulaglutide are analogs of native human GLP-1, engineered to resist the enzyme DPP-4 that normally degrades the hormone within minutes. Efpeglenatide belongs to the smaller exendin family, which also includes exenatide and lixisenatide. Exendin-4 binds the GLP-1 receptor but shares only about 53% of its sequence with human GLP-1, which makes it naturally resistant to DPP-4.
To turn a short-acting peptide into a weekly injection, Hanmi Pharmaceutical attached exendin-4 to a fragment of human immunoglobulin using the company's LAPSCOVERY carrier technology. The antibody fragment slows renal clearance and recycles the molecule through the body's natural IgG salvage pathway, stretching the half-life to roughly five to six days. The result is a once-weekly subcutaneous injection that activates the same receptor as semaglutide through a chemically distinct scaffold.
That distinction has one practical consequence worth flagging: because efpeglenatide is partly cleared by mechanisms tied to immunoglobulin handling rather than relying heavily on the kidneys, it was studied specifically in people with reduced kidney function — a population where dosing of some other agents requires caution.
The AMPLITUDE-O Cardiovascular Outcomes Trial
The centerpiece of the efpeglenatide evidence base is AMPLITUDE-O, a randomized, double-blind, placebo-controlled trial of 4,076 adults with type 2 diabetes who had either established cardiovascular disease or kidney disease plus at least one additional risk factor. Participants received weekly efpeglenatide at 4 mg or 6 mg, or placebo, on top of standard care, and were followed for a median of 1.8 years.
The primary outcome — a composite of nonfatal heart attack, nonfatal stroke, or cardiovascular death (MACE) — occurred less often in the efpeglenatide groups.
Evidence: "An incident MACE occurred in 189 participants (7.0%) assigned to efpeglenatide (3.9 per 100 person-years) and in 125 participants (9.2%) assigned to placebo (5.3 per 100 person-years), corresponding to a hazard ratio of 0.73." — Gerstein HC, et al. N Engl J Med. 2021. 10.1056/NEJMoa2108269
A 27% relative reduction in major cardiovascular events places efpeglenatide alongside the strongest results in the GLP-1 class. The kidney signal was arguably even more striking. A composite renal outcome — including new macroalbuminuria, a sustained decline in kidney filtration, or progression to kidney failure — was reduced by 32% in the efpeglenatide groups. These findings mirror and reinforce the broader cardiovascular benefits and kidney-protective effects documented across the GLP-1 class.
Benefit Held Regardless of SGLT2 Inhibitor Use
A frequent question about any new cardio-renal drug is whether its benefit disappears in patients already taking an SGLT2 inhibitor, a separate class with proven heart and kidney protection. A prespecified analysis of AMPLITUDE-O addressed this directly: the cardiovascular and kidney benefits of efpeglenatide were consistent whether or not participants were also on an SGLT2 inhibitor, suggesting the two classes may act through complementary pathways rather than competing ones.
How Much Weight Did People Lose?
Efpeglenatide was never developed primarily as an obesity drug, but every trial measured weight, and the numbers are respectable for a first-generation weekly agent. The clearest read comes from a dedicated Phase 2 study in adults without diabetes, where weight is not confounded by changes in blood glucose.
Evidence: "Over 20 weeks, all doses of efpeglenatide significantly reduced body weight from baseline versus placebo, with placebo-adjusted reductions ranging between −6.3 kg and −7.2 kg." — Pratley RE, et al. Diabetes Obes Metab. 2019. 10.1111/dom.13824
A placebo-adjusted loss of around 7 kg over five months sits between the older weekly agents and the newer generation. For comparison, in a head-to-head Phase 2 dose-ranging study, efpeglenatide was benchmarked against daily liraglutide and delivered competitive reductions in both HbA1c and body weight.
Evidence: "Once-weekly efpeglenatide produced clinically meaningful, dose-dependent reductions in HbA1c and body weight in patients with type 2 diabetes, with efficacy referenced to liraglutide." — Rosenstock J, et al. Diabetes Care. 2019. 10.2337/dc18-2648
Where It Sits Against Modern GLP-1 Drugs
The table below places efpeglenatide's weight results in context. The figures come from different trial designs and populations, so they are directional rather than head-to-head.
| Drug | Class / origin | Dosing | Typical weight change |
|---|---|---|---|
| Efpeglenatide | Exendin-based GLP-1 | Weekly injection | ~6–7 kg (placebo-adjusted, Phase 2) |
| Liraglutide | Human GLP-1 analog | Daily injection | ~5–6 kg |
| Semaglutide 2.4 mg | Human GLP-1 analog | Weekly injection | ~12–15% of body weight |
| Tirzepatide | GLP-1 / GIP dual agonist | Weekly injection | ~15–21% of body weight |
The honest interpretation: efpeglenatide's weight loss is meaningful but below what semaglutide and tirzepatide now deliver. Its differentiator was never the scale of weight loss — it was the combination of weekly dosing, cardio-renal protection, and a design that accommodated impaired kidney function.
Safety and Tolerability
The side-effect profile of efpeglenatide tracks the rest of the class. Gastrointestinal events — nausea, vomiting, and diarrhea — were the most common adverse effects and the leading reason for discontinuation, appearing early and easing with time and gradual dose escalation. In AMPLITUDE-O, gastrointestinal events were more frequent with efpeglenatide than placebo but did not translate into excess serious harm, and rates of pancreatitis, thyroid tumors, and severe hypoglycemia were low and comparable between groups.
A later analysis pooling the Phase 3 AMPLITUDE program confirmed the pattern across a wider patient base.
Evidence: "Once-weekly efpeglenatide significantly improved glycemic control and body weight, with a safety and tolerability profile consistent with the GLP-1 receptor agonist class." — Frías JP, et al. Diabetes Care. 2022. 10.2337/dc21-2656
A 2023 report of the AMPLITUDE-D, -L, and -S trials in people with suboptimally controlled type 2 diabetes reached the same conclusion, reinforcing that efpeglenatide behaves like a conventional GLP-1 agonist in real-world combinations with metformin, sulfonylureas, and insulin.
Evidence: "Efpeglenatide improved glycemic control and reduced body weight across a range of background therapies, with gastrointestinal adverse events the most commonly reported." — Aroda VR, et al. Diabetes Obes Metab. 2023. 10.1111/dom.15079
Why You Can't Get Efpeglenatide Today
Despite the AMPLITUDE-O success, efpeglenatide is not approved anywhere. Sanofi, which had licensed the drug from Hanmi, returned the rights in 2020 as part of a broader decision to exit diabetes and cardiovascular research — a strategic retreat, not a safety failure. The landmark cardiovascular trial had not yet even reported when that call was made.
Hanmi has since repositioned the molecule. Rather than re-entering the crowded diabetes market, the company filed to develop efpeglenatide specifically for obesity, submitting a Phase 3 investigational new drug application in 2024 aimed initially at the Korean population. Whether it can carve out space against semaglutide and tirzepatide — and the wave of dual and triple agonists behind them — is an open commercial question. On efficacy alone, its weight loss lags the newest agents; on cardio-renal evidence, it carries a dataset most pipeline drugs can only aspire to.
A 2025 systematic review summarized the case for reviving it, pooling eight studies across the diabetes and obesity literature.
Evidence: "Efpeglenatide offers effective glycemic control, weight reduction, cardiovascular and renal benefits, a favorable safety profile, and convenient once-weekly dosing." — Narayan N, et al. Cureus. 2025. 10.7759/cureus.77089
Key Takeaways
Efpeglenatide is the exendin-based GLP-1 that proved a point the class needed proven: heart and kidney protection is not limited to human-GLP-1 analogs. In AMPLITUDE-O it cut major cardiovascular events by 27% and kidney events by 32% in a high-risk population, with benefit preserved even alongside SGLT2 inhibitors. Its weight loss — roughly 6 to 7 kg placebo-adjusted in Phase 2 — is solid but no longer class-leading in an era of double-digit percentage reductions.
For now, efpeglenatide is a case study in how commercial timing, not clinical merit, decides which drugs reach patients. Hanmi's obesity program may yet change that. If it does, efpeglenatide would arrive not as the strongest weight-loss agent, but as one of the best-documented for protecting the heart and kidneys along the way.
References
- Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896-907. DOI: 10.1056/NEJMoa2108269
- Pratley RE, Kang J, Trautmann ME, et al. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obes Metab. 2019;21(11):2429-2439. DOI: 10.1111/dom.13824
- Rosenstock J, Sorli CH, Trautmann ME, et al. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes Care. 2019;42(9):1733-1741. DOI: 10.2337/dc18-2648
- Frías JP, Choi J, Rosenstock J, et al. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes Care. 2022;45(7):1592-1600. DOI: 10.2337/dc21-2656
- Aroda VR, Blonde L, Trautmann ME, et al. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Diabetes Obes Metab. 2023;25(9):2489-2501. DOI: 10.1111/dom.15079
- Narayan N, Vadde T, Sandesara M, et al. Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review. Cureus. 2025;17(1):e77089. DOI: 10.7759/cureus.77089
Last updated: 2026-07-12 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.